To test this hypothesis, we first focused on BTK inhibitor effects in RREAE in Biozzi mice, since BTK inhibitors have demonstrated efficacy in clinical trials with relapsing MS [35, 45]. This evidence concerns the gene BTK and myeloid sarcoma.